NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock Rated “Hold” by Wall Street Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $34.50.

A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Zacks Research lowered shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, September 14th.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the 2nd quarter worth about $54,000. Ethos Financial Group LLC grew its position in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after acquiring an additional 4,000 shares in the last quarter. Finally, AdvisorShares Investments LLC increased its stake in NRx Pharmaceuticals by 28.2% during the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after purchasing an additional 92,463 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Down 0.3%

Shares of NRx Pharmaceuticals stock opened at $2.89 on Friday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The business’s fifty day simple moving average is $3.28 and its 200-day simple moving average is $3.35. The firm has a market cap of $125.14 million, a PE ratio of -5.25 and a beta of 2.07.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million. As a group, equities analysts expect that NRx Pharmaceuticals will post -0.8 earnings per share for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations.

NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.